Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)

Mise à jour : Il y a 4 ans
Référence : NCT01510028

Femme et Homme

Extrait

The purpose of this study is to determine the safety of ascending doses of HGT-1110 administered by intrathecal (IT) injection for 38 weeks (20 injections) in children with metachromatic leukodystrophy (MLD).


Critère d'inclusion

  • Metachromatic Leukodystrophy (MLD)


Liens